Congratulations Dr. Swijnenburg for CAIRO-5 🇳🇱 presentation E-AHPBA in Lyon 👏 In unresectable #colorectalcancer #metastasis triplet FOLFOXIRI with bevacizumab or panitumumab better response, resectability and PFS than doublet #oncsurgery SSAT Society of Surgical Oncology IHPBA AHPBA

Rutger-Jan Swijnenburg

Is ICG-fluorescence 🟢 useful during #robot 🤖 and laparoscopic #liver #surgery for #CRLM? Today #MIMIC trial in JAMA Network Open Rutger-Jan Swijnenburg 🔑 Prosp study 225 pts, ICG-fluorescence imaging ⬆️ R0 resection and changed surgical management in 28% of pts. 🔑 The absence of

CAIRO5 RCT: No overall survival benefit was found for different induction regimens in patients with initially unresectable colorectal cancer liver metastases; FOLFOX/FOLFIRI plus bevacizumab is recommended. ja.ma/3Zfx1gz